Abstract
Forty-five patients with high-risk myeloid malignancies (32 acute myeloid leukemia and 13 high-risk myelodysplastic syndromes) were treated with fludarabine, cytarabine, idarubicin, and G-CSF (FLAG-IDA). Twenty-four (53%) patients achieved complete remission (CR), and five (11%) partial remission. Infection predominantly with pulmonary involvement was the most common regimen-related toxicity. Mucositis (15 patients) and pulmonary toxicity (19 patients) were the most frequently observed non-hematologic side effects. There were four early deaths and 12 patients presented with resistant disease. Overall survival (OS) at 12 months was 40%. The FLAG-IDA regimen shows evident antileukemic activity in patients with high-risk myeloid malignancies with acceptable toxicity.
MeSH terms
-
Acute Disease
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / toxicity
-
Cytarabine / administration & dosage
-
Cytarabine / toxicity
-
Female
-
Filgrastim
-
Granulocyte Colony-Stimulating Factor / administration & dosage
-
Granulocyte Colony-Stimulating Factor / toxicity
-
Humans
-
Idarubicin / administration & dosage
-
Idarubicin / toxicity
-
Infections / chemically induced
-
Infections / pathology
-
Leukemia, Myeloid / drug therapy*
-
Leukemia, Myeloid / mortality
-
Male
-
Middle Aged
-
Myelodysplastic Syndromes / drug therapy*
-
Myelodysplastic Syndromes / mortality
-
Recombinant Proteins
-
Remission Induction
-
Risk Factors
-
Survival Analysis
-
Treatment Outcome
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives*
-
Vidarabine / toxicity
Substances
-
Recombinant Proteins
-
Cytarabine
-
Granulocyte Colony-Stimulating Factor
-
Vidarabine
-
Filgrastim
-
Idarubicin